高分辨率磁共振管壁成像评估他汀类药物对动脉粥样硬化病变治疗效果的研究进展

摘要/Abstract

摘要：

研究显示高分辨率磁共振成像技术能够准确定性和定量分析动脉粥样硬化斑块的负荷和成分特征，并具有高度可重复性，已被广泛应用于监测他汀类药物对动脉粥样硬化斑块治疗效果的临床试验中。本文将从高分辨率磁共振的成像方法、可重复性以及观察他汀类药物对动脉粥样硬化斑块疗效方面的研究进行综述，总结该技术在评估药物治疗动脉粥样硬化斑块疗效方面的应用价值。

文章导读： 高分辨率磁共振管壁成像可以动态监测不同他汀类药物、同种药物不同剂量、多种药物联合治疗对动脉粥样硬化斑块的效果。

关键词: 磁共振成像; 高分辨; 动脉粥样硬化斑块; 他汀

Abstract:

A number of studies demonstrated that high resolution magnetic resonance imaging (HRMRI) is accurately capable of evaluating atherosclerotic plaque burden and compositions qualitatively and quantitatively. In addition, HRMRI is an imaging technique with high reproducibility which has been largely utilized to monitor the treatment effect of statin for atherosclerotic diseases in clinical trials. This review will summarize the characteristics of HRMRI techniques, studies on reproducibility and clinical trials where this technique was used to monitor the treatment effect of statin for atherosclerotic diseases.

Key words: Magnetic resonance imaging, High resolution; Atherosclerotic plaque; Statin

庄仲，彭晓刚，赵锡海. 高分辨率磁共振管壁成像评估他汀类药物对动脉粥样硬化病变治疗效果的研究进展[J]. 中国卒中杂志, 2016, 11(03): 229-234.

ZHUANG Zhong, PENG Xiao-Gang,ZHAO Xi-Hai. Advances in Assessment of Treatment Effect of Statin for Atherosclerotic Diseases by High Resolution Magnetic Resonance Vessel Wall Imaging[J]. Chinese Journal of Stroke, 2016, 11(03): 229-234.

参考文献

1 管懋彬, 赵锡海, 杜芳, 等. 卒中相关的粥样硬化易损

斑块的病理与分布特点研究进展[J]. 中国卒中杂志,

2015, 10:243-247.

2 Gupta S. LDL cholesterol, statins and PC SK 9

inhibitors[J]. Indian Heart J, 2015, 67:419-424.

3 董莉, 于薇, 濮欣, 等. 高分辨MRI技术对动脉粥样硬

化斑块的评价[J]. 中国卒中杂志, 2014, 9:152-157.

4 王忠艳, 高培毅, 隋滨滨, 等. 颈动脉粥样硬化疾病的

高分辨磁共振成像研究进展[J]. 中国卒中杂志, 2014,

9:445-449.

5 Saam T, Kerwin WS, Chu B, et al. Sample size

calculat ion for clinical t r ials using magnet ic

resonance imaging for the quantitative assessment of

carotid atherosclerosis[J]. J Cardiovasc Magn Reson,

2005, 7:799-808.

6 Zhao X, Underhill HR, Yuan C, et al. Minimization

of MR contrast weightings for the comprehensive

evaluation of carotid atherosclerotic disease[J]. Invest

Radiol, 2010, 45:36-41.

7 Takaya N, Cai J, Ferguson MS, et al. Intra- and

interreader reproducibility of magnetic resonance

imaging for quantifying the lipid-rich necrotic core is

improved with gadolinium contrast enhancement[J]. J

Magn Reson Imaging, 2006, 24:203-210.

8 Touzé E, Toussaint JF, Coste J, et al. Reproducibility

of high-resolution MRI for the identification and

the quantification of carotid atherosclerotic plaque

components:consequences for prognosis studies and

therapeutic trials[J]. Stroke, 2007, 38:1812-1819.

9 Sa am T, Fe rg uson MS, Ya r nyk h VL, e t a l .

Quantitative evaluation of carotid plaque composition

by in vivo MRI[J]. Arterioscler Thromb Vasc Biol,

2005, 25:234-239.

10 Cai J, Hatsukami TS, Ferguson MS, et al. In vivo

quantitative measurement of intact f ibrous cap

and lipid-rich necrotic core size in atherosclerotic

carotid plaque:compar ison of high-resolution,

contrast-enhanced magnetic resonance imaging and

histology[J]. Circulation, 2005, 112:3437-3444.

11 Kerwin WS, O'Brien KD, Ferguson MS. Inflammation

in carotid atherosclerotic plaque:a dynamic contrastenhanced

MR imaging study[J]. Radiology, 2006,

241:459-468.

12 Kerwin WS, Oikawa M, Yuan C. MR imaging of

adventitial vasa vasorum in carotid atherosclerosis[J].

Magn Reson Med, 2008, 59:507-514.

13 EI Aidi H, Mani V, Weinshelbaum KB, et al. Crosssectional,

prospective study of MRI reproducibility in

the assessment of plaque burden of the carotid arteries

and aorta[J]. Nat Clin Pract Cardiovasc Med, 2009,6:219-228.

14 Varghese A, Crowe LA, Mohiaddin RH, et al.

Interstudy reproducibility of three-dimensional

volume-selective fast spin echo magnetic resonance

for quantifying carotid artery wall volume[J]. J Magn

Reson Imaging, 2005, 21:187-191.

15 Li F, Yarnykh VL, Hatsukami TS, et al. Scan-rescan

reproducibility of carotid atherosclerotic plaque

morphology and tissue composition measurements

using multicontrast MRI at 3T[J]. J Magn Reson

Imaging, 2010, 31:168-176.

16 Saam T, Yuan C, Chu B, et al. Predictors of carotid

atherosclerotic plaque progression as measured

by noninvasive magnetic resonance imaging[J].

Atherosclerosis, 2007, 194:e34-e42.

17 Underhill HR, Yuan C, Zhao XQ, et al. Effect of

rosuvastatin therapy on carotid plaque morphology

and composition in moderately hypercholesterolemic

patients:a high-resolution magnetic resonance imaging

trial[J]. Am Heart J, 2008, 155:584, e581-588.

18 Du R, Cai J, Zhao XQ, et al. Early decrease in

carotid plaque lipid content as assessed by magnetic

resonance imaging during treatment of rosuvastatin[J].

BMC Cardiovasc Disord, 2014, 14:83.

19 Lee JM, Robson MD, Yu LM, et al. Effects of highdose

modified-release nicotinic acid on atherosclerosis

and vascular function:a randomized, placebocontrolled,

magnetic resonance imaging study[J]. J

Am Coll Cardiol, 2009, 54:1787-1794.

20 Corti R, Fayad ZA, Fuster V, et al. Effects of lipidlowering

by simvastatin on human atherosclerotic

lesions:a longitudinal study by high-resolution,

noninvasive magnet ic resonance imaging[J ].

Circulation, 2001, 104:249-252.

21 Corti R, Fuster V, Fayad ZA, et al. Lipid lowering

by simvastat in induces regression of human

atherosclerotic lesions:two years' follow-up by highresolution

noninvasive magnetic resonance imaging[J].

Circulation, 2002, 106:2884-2887.

22 Sibley CT, Vavere AL, Got tlieb I, et al. MRImeasured

regression of carotid atherosclerosis induced

by statins with and without niacin in a randomised

controlled trial:the NIA plaque study[J]. Heart, 2013,

99:1675-1680.

23 Cor ti R, Fuster V, Fayad ZA, et al. Effects of

aggressive versus conventional lipid-lowering therapy

by simvastatin on human atherosclerotic lesions:a

prospective, randomized, double-blind trial with highresolution

magnetic resonance imaging[J]. J Am Coll

Cardiol, 2005, 46:106-112.

24 Yonemura A, Momiyama Y, Fayad ZA, et al. Effectof lipid-lowering therapy with atorvastatin on

atherosclerotic aortic plaques detected by noninvasive

magnetic resonance imaging[J]. J Am Coll Cardiol,

2005, 45:733-742.

25 Lee JM, Wiesmann F, Shirodaria C, et al. Early

changes in arterial structure and function following

statin initiation:quantification by magnetic resonance

imaging[J]. Atherosclerosis, 2008, 197:951-958.

26 Yonemura A, Momiyama Y, Fayad ZA, et al. Effect

of lipid-lowering therapy with atorvastatin on

atherosclerotic aortic plaques:a 2-year follow-up by

noninvasive MRI[J]. Eur J Cardiovasc Prev Rehabil,

2009, 16:222-228.

27 Migrino RQ, Bowers M, Harmann L, et al. Carotid

plaque regression fol lowing 6 -mont h stat in

therapy assessed by 3T cardiovascular magnetic

resonance:comparison with ultrasound intima media

thickness[J]. J Cardiovasc Magn Reson, 2011, 13:37.

28 Zhao XQ, Dong L, Hat sukami T, e t a l. MR

imaging of carotid plaque composition during

lipid-lowering therapy a prospective assessment

of effect and time course[J]. JACC Cardiovasc

Imaging, 2011, 4:977-986.

29 Lima JA, Desai MY, Steen H, et al. Statin-induced

cholesterol lowering and plaque regression after 6

months of magnetic resonance imaging-monitored

therapy[J]. Circulation, 2004, 110:2336-2341.

30 Gottlieb I, Agarwal S, Gautam S, et al. Aortic plaque

regression as determined by magnetic resonance

imaging with high-dose and low-dose statin therapy[J].

J Cardiovasc Med (Hagerstown), 2008, 9:700-706.

31 McGill HC Jr, Mc Mahan CA, Malcom GT, et

al. Effects of serum lipoproteins and smoking on

atherosclerosis in young men and women. The PDAY

Research Group. Pathobiological Determinants of

Atherosclerosis in Youth[J]. Arterioscler Thromb Vasc

Biol, 1997, 17:95-106.

32 Kawahara T, Nishikawa M, Furusawa T, et al. Effect

of atorvastatin and etidronate combination therapy on

regression of aortic atherosclerotic plaques evaluated

by magnetic resonance imaging[J]. J Atheroscler

Thromb, 2011, 18:384-395.

33 West AM, Anderson JD, Meyer CH, et al. The effect

of ezetimibe on peripheral arterial atherosclerosis

depends upon statin use at baseline[J]. Atherosclerosis,

2011, 218:156-162.

[1]	鲁燕, 杨保荣, 黄向萍, 杨冠桂, 陈圣文, 李建荣, 曾小明. 县级医院急性缺血性卒中超时间窗经MRI筛选溶栓的病例对照研究 [J]. 中国卒中杂志, 2022, 17(12): 1321-1326.
[2]	索阅, 张喆, 谢雪微, 孔庆乐, 王拥军, 荆京. 7.0T MRI在脑血管病中的应用进展[J]. 中国卒中杂志, 2022, 17(11): 1257-1263.
[3]	陈扬, 张婧, 陈芬, 丁杏, 陈昆涛. 卒中缺血性半暗带功能磁共振成像评估的研究进展[J]. 中国卒中杂志, 2022, 17(11): 1264-1270.
[4]	向薇, 徐璐瑶, 张曼曼, 魏红春, 梁志刚. 缺血性卒中急性期磁敏感加权成像不对称突出静脉征的发生率及影响因素分析[J]. 中国卒中杂志, 2022, 17(10): 1097-1102.
[5]	刘伊桐, 黄燕琪, 李明利, 冯逢, 高山, 徐蔚海. 颈动脉几何形态——60岁及以下无高危因素人群颅内动脉粥样硬化的潜在预测指标[J]. 中国卒中杂志, 2022, 17(09): 925-931.
[6]	简晓莉, 邓肖, 白雪. 延髓最后区综合征合并急性脑干综合征发病的视神经脊髓炎谱系疾病1例报道[J]. 中国卒中杂志, 2022, 17(09): 1007-1010.
[7]	徐璐瑶, 陈晓迪, 梁志刚. 卒中后失语的影像学评估研究进展[J]. 中国卒中杂志, 2022, 17(09): 1017-1021.
[8]	张倩, 张冠一, 张佳, 陈胜云, 赵性泉. 空腹血糖对无症状颈动脉粥样硬化斑块患者认知功能的影响—— 1项针对非城镇居民的调查[J]. 中国卒中杂志, 2022, 17(07): 753-757.
[9]	李琳琳, 吴娱倩, 张英魁. 大脑中动脉原位血栓磁共振成像多序列评估与信号解读[J]. 中国卒中杂志, 2022, 17(05): 544-547.
[10]	叶益超, 玉石, 佘亚军, 方正, 王毅. 血管性帕金森综合征的研究进展[J]. 中国卒中杂志, 2022, 17(04): 346-350.
[11]	毕京凤, 李琳琳, 刘欣瑶, 张英魁. 颈部动脉夹层磁共振成像多序列评估与信号解读[J]. 中国卒中杂志, 2022, 17(04): 402-406.
[12]	李昕, 张英魁, 曹康熙, 袁庆海. 1例青年卒中患者的多模态影像检查[J]. 中国卒中杂志, 2022, 17(03): 314-317.
[13]	张长青, 李子孝, 王春娟, 赵性泉, 王伊龙, 王拥军. 他汀类药物服用持续性对缺血性卒中患者复发的影响[J]. 中国卒中杂志, 2022, 17(02): 122-127.
[14]	刘欣瑶, 毕京凤, 张英魁. 脑出血信号改变机制与磁共振影像表现[J]. 中国卒中杂志, 2021, 16(12): 1217-1221.
[15]	凌一童, 张晓宇, 辛华, 张文婧, 董丽华. 以头晕为首发症状的双侧延髓内侧梗死2例[J]. 中国卒中杂志, 2021, 16(12): 1268-1272.